---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-031202"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:34:51.952048+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex completes 0.09 mg/kg dose in Phase 1 Acclaim-3 trial; SRC approves escalation to highest dose

## Summary
- Completed 0.09 mg/kg dose group of Reqorsa + Tecentriq in ES-SCLC Phase 1; no dose-limiting toxicities reported.
- Safety Review Committee approved escalation to 0.12 mg/kg, the highest planned dose group.
- Phase 2 expansion will enroll 50 patients at 10-15 U.S. sites; primary endpoint is 18-week PFS rate.
- Acclaim-3 has FDA Fast Track and Orphan Drug Designations for this patient population.
- Company expects to start Phase 2 expansion in H2 2024, pending enrollment in the 0.12 mg/kg cohort.

## SEC filing metadata
- accession: 0001437749-24-031202
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774924031202/0001437749-24-031202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774924031202/gnpx20241009_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-031202
- JSON: https://secwatch.observer/filing/0001437749-24-031202.json
- Plain text: https://secwatch.observer/filing/0001437749-24-031202.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.